Apr 2020 – Apr 2025 · 5 yrs · Paris, France

Dec 2016 – Apr 2020 · 3 yrs 4 mos · United States

• At BCH, I am currently responsible for developing a short, mid- and long-term R&D pipeline of innovation that include new products/technology/devices, packaging & claims for the ~2.8billion euros Therapeutics Portfolio of the Consumer Health division. The categories I have responsibility for include digestive health, allergy, pain management, cough and cold, and cardio. I oversee a staff of about 110 employees. Provide technical support for Switch. Focused on building a high performing team with a strong innovation and engaged mindset (culture), and the appropriate capabilities to drive value and growth across the portfolio.

Oct 2015 – Dec 2016 · 1 yr 2 mos

Jan 2012 – Oct 2015 · 3 yrs 9 mos

• Promoted to lead the global switch of Nexium Rx as well as guide innovation pipeline development to position Nexium as a global OTC brand. Tasked with building the entire R&D team from the ground up to a high-performing team of 15. Serve as Alliance R&D lead to support commercialization of Nexium while ensuring alignment with the global Rx strategy.
• Led the Rx to OTC switch of Nexium in the US and EU in partnership with AstraZeneca. Identified key influencers and expert advisors to cultivate support for OTC switch products (specifically Nexium).
• Built an unprecedented alliance with AstraZeneca: Created governance models within the alliance to rapidly and effectively resolve issues.
• Established and built global innovation portfolio set to deliver $1B revenue objective for Nexium OTC in collaboration with commercial lead.
• Forged relationships with key influencers and opinion leaders within Pfizer and external organizations (such as the Federation of International Pharmacists and the Worldwide Gastroenterology Organisation) to champion the concept of self-care and acceptance of global OTC switch products.
• Defined the global brand strategy for Nexium OTC, including claims and innovation portfolio in partnership with the Commercial Lead.
• Received the Healthcare Business Women’s Association Award in 2014 recognizing the successful launch of Female Leadership Initiative Program (FLIP) in 2008 and an ongoing commitment to the advancement and growth of women in Pfizer.

Jan 2010 – Jan 2012 · 2 yrs

• Promoted to guide R&D function for the Upper Respiratory category during the company's reorganization into four separate franchises. Gained buy in from senior leaders to invest in the respiratory business. Led team of 10 medical and product design colleagues/leaders to define brand strategy and establish innovation portfolio to support growth for the respiratory franchise.
• Defined and led opportunities for geographic expansion of key respiratory brands (Robitussin and Advil Respiratory) into Europe, Latin America, and China.
• Appointed to leadership committee to support Global Franchise Team governance structure development.
• Served as the R&D lead for the Respiratory Global Franchise team, responsible for over $400M of Respiratory business, tasked with defining global brand strategy and innovation pipeline to support growth and geographic expansion for Robitussin and Advil Respiratory brands.
• Provided guidance for 9+ respiratory launches from 2010-2012, including: Advil Congestion Relief (the first PCH-approved NDA), Robitussin multi-symptom allergy sinus suspension (launched in China), and Robitussion CFmax.
• R&D Lead for Pfizer's pitch to secure Nexium's OTC license from AstraZeneca, competing against industry leaders such as Johnson & Johnson and Procter and Gamble to become a partner of choice. Defined future growth opportunities and innovation pipeline for Nexium in the OTC space.

Jan 2008 – Jan 2010 · 2 yrs

• Associate R&D Director II, Global Analgesics Product Development Team Leader (2009 - 2010) | Associate R&D Director I, Respiratory and Analgesics Product Development Group (2008 - 2009)
• Managed cross-functional product development groups of analytical and formulation scientists within Analgesics and Respiratory therapeutic areas. Promoted in 2009 to partner with international business unit for respiratory & analgesics product development with emphasis on APAC and LatAm, repeating earlier successes on a larger, global scale.
• Oversaw and designed experiments that focused on stability, manufacturability and commercialization potential of new products; identified and resolved technical issues; determined IP strategies and opportunities; managed clinical trial manufacture; participated in PAI audits; and ramped up production to support commercialization to deliver on key timelines and regulatory requirements. Matrix accountability for Product Development, QA, R&D, Project Planning, Patent Law, Technical Services, and Marketing.
• Defined development, regulatory, clinical, technical, and IP property strategy as Project Team Lead for a key analgesics extended-release program, Advil IR/ER.
• Managed multiple third party product development programs within and outside the US, which have included both monograph and NDA regulatory categories, from prototype development to process validation and launch.
• Led cross-functional Due Diligence teams to evaluate third party sites and their systems for development capabilities for various dosage forms (liquids, suspensions, tablets, and soft gels). At the Associate Director II level, focused on high-level assessment of leadership capabilities and cultural fit.

Jan 2005 – Jan 2007 · 2 yrs

• Recognized for strong business and technical acumen, transitioned to business leadership role, and similarly promoted to increasingly complex leadership role to guide product development for Dimetapp and Robitussin products.
• Selected to lead international development program in China.
• Guided several launches and 2 agency approvals within the Respiratory business for China, earning a Global Excellence Award nomination.
• Named to various HR-related teams to support staff development and training.
• Named Brand Equity Team (BET) Leader in 2006, supporting PCH's existing global brands and developing New Project Proposal (NPP) line extensions for key brands in the Respiratory, Analgesics and Personal Care categories.

Jan 1998 – Jan 2005 · 7 yrs

• Principal Scientist (2003 - 2005) | Sr. Research and Development Scientist (2001 - 2003) | Research Scientist (1998 - 2001)
• Joined Pfizer (then Wyeth) in 1998 as Research Scientist to focus on prototype development, technology transfer, and dossier development for commercialization. Transitioned to Senior R&D Scientist and Principal Scientist to guide product development, production scale-up, and technology transfer of numerous tablets and suspensions. Authored IND and NDA submission documents and supported PAI readiness activities. Led team of 4-7 and served as mentor and trainer to junior R&D staff.
• Primary scientist responsible for prototype development, technology transfer and launches of three syrup monograph products and one sNDA ibuprofen suspension. Led development, production scale-up, technology transfer and launch of the first multi-active NDA tablet formulation.
• Led the company's first product development and technology transfer of an NDA multi-active tablet and suspension (Advil Multi-symptom Allergy Sinus) from Wyeth, Richmond to the Asia Pacific region. Interfaced with APAC regulatory, operations, tech services, project management, QA, and marketing teams to ensure successful product registration.
• Supported the licensing of two active-extended release formulations from contract manufacturer in China.
• Led the European Monograph Initiative Team, charged with harmonizing raw material monographs across EP and USP requirements, ensuring EP status of future and ongoing projects.
• Selected to serve as product development representative for Brand Equity Team, tasked with managing respiratory, analgesics, and personal care products.